{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:35:29Z","timestamp":1787070929679,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Image guided radiotherapy (IGRT) is one of the most commonly used treatment in LAPC. Dose escalation &gt;74 Gy has shown to improve the biochemical control and freedom from failure rate in LAPC.We started treating LAPC patients with dose escalated IGRT in our institute since 2008. We did a retrospective analysis to see the biochemical relapse-free survival, cancer-specific survival, and bladder and rectal toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A total of 50 consecutive prostate cancer patients were treated with dose escalated IGRT between January 2008 to Dec 2013. Out of these, 37 patients of LAPC were analyzed and their medical records were retrieved. All were biopsy proven adenocarcinoma of prostate with D\u2019Amico high risk category (PSA &gt;20 ng\/mL or Gleason score (GS) &gt;7 or T2c-T4). Three gold fiducial markers were placed in the prostate. Patients were immobilized in supine position with either ankle or knee rest. Partial bladder filling and rectum emptying protocol was followed. Clinical target volume (CTV) segmentation was done according to EORTC recommendation. Population based PTV expansion from CTV of 10 mm (cranio-caudal), 10 mm (medio-lateral), 10 mm (anterior) and 5 mm (posterior) was given. In patients with radiologically enlarged pelvic lymph node, whole pelvis intensity modulated radiation therapy (IMRT) to a dose of 50.4 Gy\/28# followed by prostatic boost 26Gy\/13# by IMRT using image guidance. Rest of the patients received prostate only RT to a dose of 76Gy\/38# by IGRT. Daily On board KV images were taken and 2D-2D fiducial marker matching was done and shifts were applied on machine before treatment. Biochemical relapse was defined as per Phoenix definition (nadir + 2 ng\/mL). Radiation Therapy Oncology Group (RTOG) toxicity grading system was used to document acute and late toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Median age of patients was 66 years. Median pre-treatment PSA was 22 ng\/mL. Thirty patients (81%) had T3\/T4 lesions and nodal metastasis was seen in 11 (30%). Median GS was 8. Median radiotherapy dose was 76 Gy. Imaging before radiation delivery was done in 19(51%) patients and 100% in 14 (38%) patients. With a median follow up of 6.5 years, 5-year biochemical relapse-free survival (bRFS) and cancer-specific survival (CSS) was 66% and 79% respectively. Mean bRFS and CSS were 71 months and 83 months however Median bRFS and CSS were not reached. Distant metastasis was seen in 8 (22%). RTOG grade III bladder and rectal toxicity was seen in 2 (6%) and 2 (6%) patients respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Dose escalated IGRT with fiducial marker positional verification for LAPC is doable in Indian setup provided more emphasis given on daily on-board imaging with rigorous bladder filling and rectal emptying protocol. Long term follow up is needed to assess the effect on distant disease-free survival and CSS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_1531_22","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T01:20:32Z","timestamp":1686619232000},"page":"382-388","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A dose escalated fiducial marker-based image guided radical radiotherapy in locally advanced prostate cancers: A single institute experience from India"],"prefix":"10.4103","volume":"19","author":[{"given":"Pramod K.","family":"Gupta","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Kalyan Singh Super Speciality Cancer Institute, Lucknow, India"},{"name":"Department of Radiotherapy, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Rastogi","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koilpillai Joseph Maria","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaleen","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"key":"R1-20241021","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R4-20241021","doi-asserted-by":"crossref","first-page":"6245","DOI":"10.7314\/APJCP.2012.13.12.6245","article-title":"Estimation of time trends of incidence of prostate cancer--An Indian scenario","volume":"13","author":"Lalitha","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"key":"R5-20241021","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0360-3016(98)00091-1","article-title":"Dose escalation with three dimensional conformal radiation therapy affects the outcome in prostate cancer","volume":"41","author":"Zelefsky","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R6-20241021","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0360-3016(02)02857-2","article-title":"High-dose intensity modulated radiation therapy for prostate cancer:Early toxicity and biochemical outcome in 772 patients","volume":"53","author":"Zelefsky","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R7-20241021","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.294.10.1233","article-title":"Comparison of conventional- dose vs. high- dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate:A randomized controlled trial","volume":"294","author":"Zietman","year":"2005","journal-title":"JAMA"},{"key":"R8-20241021","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.juro.2006.06.002","article-title":"Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer","volume":"176","author":"Zelefsky","year":"2006","journal-title":"J Urol"},{"key":"R9-20241021","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ijrobp.2007.01.008","article-title":"What dose of external-beam radiation is high enough for prostate cancer?","volume":"68","author":"Eade","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R10-20241021","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1470-2045(07)70143-2","article-title":"Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer:First results from the MRC RT01 randomised controlled trial","volume":"8","author":"Dearnaley","year":"2007","journal-title":"Lancet Oncol"},{"key":"R11-20241021","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.semradonc.2007.09.007","article-title":"Intensity-modulated radiationtherapy:Supportive data for prostate cancer","volume":"18","author":"Cahlon","year":"2008","journal-title":"Semin Radiat Oncol"},{"key":"R12-20241021","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ijrobp.2008.04.063","article-title":"Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer","volume":"73","author":"Al-Mamgani","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R13-20241021","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4103\/0973-1482.16088","article-title":"Three dimensional conformal radiation therapy in prostate adenocarcinoma:Survival and rectal toxicity","volume":"1","author":"Kannan","year":"2005","journal-title":"J Cancer Res Ther"},{"key":"R14-20241021","doi-asserted-by":"crossref","first-page":"277","DOI":"10.4103\/0973-1482.59909","article-title":"Dose escalation in image-guided, intensity modulated radiotherapy of carcinoma prostate:Initial experience in India","volume":"5","author":"Kumara","year":"2009","journal-title":"J Cancer Res Ther"},{"key":"R15-20241021","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4103\/0973-1482.63565","article-title":"High-dose intensity-modulated radiotherapy as primary therapy for prostate cancer:Report on dosimetry aspects and acute toxicity in the Indian scenario","volume":"6","author":"De","year":"2010","journal-title":"J Cancer Res Ther"},{"key":"R16-20241021","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D'Amico","year":"1998","journal-title":"JAMA"},{"key":"R18-20241021","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.radonc.2006.05.012","article-title":"Guidelines for primary radiotherapy of patients with prostate cancer","volume":"79","author":"Boehmer","year":"2006","journal-title":"Radiother Oncol"},{"key":"R19-20241021","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer:Recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R20-20241021","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.ijrobp.2009.07.1754","article-title":"Use of normal tissue complication probability models in the clinic","volume":"76","author":"Marks","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R21-20241021","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R22-20241021","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.radonc.2017.04.003","article-title":"Improved outcomes with dose escala-tion in localized prostate cancer treated with precision image-guided radio-therapy","volume":"123","author":"Raziee","year":"2017","journal-title":"Radiother Oncol"},{"key":"R23-20241021","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4103\/0973-1482.131342","article-title":"Image guidance in prostate cancer-can offline corrections be an effective substitute for daily online imaging?","volume":"10","author":"Mallick","year":"2014","journal-title":"J Cancer Res Ther"},{"key":"R24-20241021","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ijrobp.2015.09.035","article-title":"Physics contribution image guided radiation therapy (IGRT) practice patterns and IGRT's impact on workflow and treatment planning:Results from a national survey of American Society for Radiation Oncology members","volume":"94","author":"Nabavizadeh","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R25-20241021","doi-asserted-by":"crossref","first-page":"20160059","DOI":"10.1259\/bjr.20160059","article-title":"Image-guided radiotherapy for prostate cancer in the United Kingdom:A national survey","volume":"90","author":"Ariyaratne","year":"2017","journal-title":"Br J Radiol"},{"key":"R26-20241021","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.clon.2019.05.020","article-title":"Prostate radiotherapy in India:Evolution, practice and challenges in the 21st century","volume":"31","author":"Murthy","year":"2019","journal-title":"Clin Oncol"},{"key":"R27-20241021","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijrobp.2007.09.020","article-title":"Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer","volume":"71","author":"Kupelian","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R28-20241021","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.prro.2017.09.010","article-title":"Effect of imaging frequency on PTV margins and geographical miss during image guided radiation therapy for prostate cancer","volume":"8","author":"Gupta","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"R29-20241021","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4103\/0973-1482.131342","article-title":"Image guidance in prostate cancer-can offline corrections be an effective substitute for daily online imaging?","volume":"10","author":"Prasad","year":"2014","journal-title":"J Can Res Ther"},{"key":"R30-20241021","doi-asserted-by":"crossref","first-page":"20160296","DOI":"10.1259\/bjr.20160296","article-title":"Fiducial marker guided prostate radiotherapy:A review","volume":"89","author":"O'Neill","year":"2016","journal-title":"Br J Radiol"},{"key":"R31-20241021","first-page":"15","article-title":"Fiducial markers in prostate cancer image-guided radiotherapy","volume":"33","author":"Ghaffari","year":"2019","journal-title":"Med J Islam Repub Iran"},{"key":"R32-20241021","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with localized prostate cancer (HYPRO):Final efficacy results from a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Incrocci","year":"2016","journal-title":"Lancet Oncol"},{"key":"R33-20241021","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionatedhigh-dose intensity-modulated radiotherapy for prostatecancer:5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"R34-20241021","first-page":"40","article-title":"Patient reported toxicity and quality of life after hypofractionated high-dose intensity-modulated radiotherapy for intermediate- and high risk prostate cancer","volume":"29","author":"Houben","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"key":"R35-20241021","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/03915603211042335","article-title":"Radiation therapy for prostate cancer:What's the best in 2021","volume":"89","author":"Cellini","year":"2022","journal-title":"Urologia J"},{"key":"R36-20241021","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT):Outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"key":"R37-20241021","doi-asserted-by":"crossref","first-page":"6936","DOI":"10.18632\/aging.202551","article-title":"Hypofractionated versus conventionally fractionated image-guided volumetric-modulated arc radiotherapy for localized prostate cancer:A phase II randomized trial from China","volume":"13","author":"Zhong","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"R38-20241021","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4103\/aort.aort_28_21","article-title":"A prospective observational study on Hypo-fractionated radical radiotherapy for non-metastatic prostate cancer using image guided radiotherapy:Assessing the toxicity and quality of life","volume":"2","author":"Kunheri","year":"2022","journal-title":"Ann Oncol Res Ther"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1531_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:39:06Z","timestamp":1787067546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1531_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1531_22","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"2022-07-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}